Industry has undue influence on academic collaboration and safeguards need strengthening: White Coat. . . Which Hat

摘要

Well-known and respected drug companies pay billions in fines for breaking the rules. Key opinion leaders crisscross the globe, touting the latest drug or device with inadequate disclosure. Recently FDA-approved drugs are withdrawn after problems surface, often recognized but ignored by the drug company. Multifocal lens implants, after enthusiastic introductions by talking heads, fall by the wayside when disabling visual side effects emerge. Who can doubt that industry has too much influence on ophthalmology's academic activities and that safeguards need to be stronger and relationships more transparent?